Related Experiment Videos
Interleukin 13: a growth factor in hodgkin lymphoma
B F Skinnider1, U Kapp, T W Mak
1Amgen Institute, Ontario Cancer Institute and the Departments of Medical Biophysics and Immunology, University of Toronto, Toronto, Canada.
Insights
Interleukin-13 (IL-13) fuels the growth of Reed-Sternberg cells in classical Hodgkin lymphoma (cHL). Blocking IL-13 signaling inhibits cancer cell proliferation and promotes apoptosis, offering a potential therapeutic target for cHL.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Classical Hodgkin lymphoma (cHL) is a lymph node malignancy characterized by Reed-Sternberg (RS) cells.
- RS cells are believed to drive cHL pathogenesis through abnormal cytokine production.
- Interleukin-13 (IL-13) has been identified as a frequently expressed cytokine in HL.
Purpose of the Study:
- To investigate the role of IL-13 as an autocrine growth factor for RS cells in cHL.
- To examine the expression of IL-13 and its receptor (IL-13Rα1) in HL cell lines and primary samples.
- To assess the impact of IL-13 neutralization on RS cell proliferation and apoptosis.
Main Methods:
- Analysis of IL-13 and IL-13Rα1 expression in HL cell lines and RS cells from biopsy specimens.
- In vitro experiments neutralizing IL-13 in cultured HL cell lines (HDLM-2, L-1236).
- Assessment of cell proliferation and apoptosis following IL-13 blockade.
- Evaluation of Signal Transducer and Activator of Transcription (STAT) 6 phosphorylation (P-STAT6) as a marker of IL-13 signaling.
Main Results:
- IL-13 and IL-13Rα1 are commonly expressed in HL-derived cell lines and RS cells.
- Neutralization of IL-13 significantly inhibits proliferation of HL cell lines in a dose-dependent manner.
- IL-13 blockade increases apoptosis in L-1236 cells.
- STAT6 is constitutively activated in HL cell lines and phosphorylated in primary RS cells, indicating active IL-13 signaling in vivo.
- Coexpression of IL-13, IL-13Rα1, and P-STAT6 is rare in non-Hodgkin lymphomas.
Conclusions:
- IL-13 functions as an autocrine growth factor for RS cells in classical Hodgkin lymphoma.
- IL-13 signaling, mediated by STAT6, plays a crucial role in cHL pathogenesis.
- Targeting the IL-13/STAT6 pathway presents a potential therapeutic strategy for cHL.
Abstract:
Classical Hodgkin lymphoma (cHL) is a malignant disorder of lymph nodes with distinctive clinical and pathologic features. These features are thought to be primarily due to the abnormal production of multiple cytokines by the malignant cell population of HL, the Reed-Sternberg (RS) cells. We have previously demonstrated that interleukin (IL)-13 expression is a common feature of HL and have studied its role as an autocrine growth factor for RS cells. IL-13 and IL-13R(alpha)1, the IL-13-specific receptor chain, are frequently expressed by HL-derived cell lines and by RS cells from biopsy material of tissues involved by HL. Neutralization of IL-13 in cultures of the HL-derived cell lines HDLM-2 and L-1236 leads to a dose-dependent inhibition of proliferation, and is associated with increased apoptosis in L-1236 cells. Signal transducer and activator of transcription (STAT) 6 is an important mediator of IL-13 signaling. STAT6 is constitutively activated in HL cell lines due to autocrine secretion of IL-13. STAT6 is also phosphorylated (P-STAT6) in RS cells from many primary HL samples, supporting the hypothesis that IL-13 signaling occurs in these malignant cells in vivo. Coexpression of IL-13, IL-13R(alpha)1 and P-STAT6 is uncommon in non-Hodgkin lymphomas. Following a description of the clinical and pathologic features of HL, this review will discuss the function of IL-13 as an autocrine growth factor for RS cells in HL and its potential role in mediating other features of this disease.